|
| Tuesday, 24 May 2016, 09:19 HKT/SGT | |
| |  | |
Source: Eisai | |
|
|
|
TOKYO, May 24, 2016 - (JCN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that a series of abstracts highlighting new study results on Halaven (eribulin mesylate; halichondrin class microtubule dynamics inhibitor, "eribulin") and Lenvima (lenvatinib mesylate; selective inhibitor of receptor tyrosine kinases (RTKs) with a novel binding mode, "lenvatinib") will be presented during the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place in Chicago, the United States, from June 3 to 7, 2016.
Poster presentations for this year's ASCO meeting include a presentation highlighting the results of a Phase I clinical study of eribulin liposomal formulation in solid tumors. Presentations for lenvatinib include updated results from the SELECT study regarding response to lenvatinib treatment in patients with radioiodine-refractory differentiated thyroid cancer as well as final analysis results of a Phase II study of lenvatinib in patients with differentiated, medullary, and anaplastic thyroid cancer.
Eisai positions oncology as a key franchise area. The company will continue to create innovation in the development of new drugs based on cutting-edge cancer research, and in doing so seeks to make further contributions to address the diversified needs of, and increase the benefits provided to, patients and their families as well as healthcare providers.
Contact:
Public Relations Department,
Eisai Co., Ltd.
+81-3-3817-5120
Topic: Press release summary
Source: Eisai
Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network
Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
|
|
|
